瑞舒伐他汀治疗老年冠心病患者高胆固醇血症的疗效及安全性研究

Efficacy and safety of rosuvastatin in aged patients with coronary heart disease and hypercholesterolemia

目的 评价瑞舒伐他汀治疗老年冠心病患者高胆固醇血症的疗效及按入院次序安全性,并与辛伐他汀作对比.方法 采用单盲随机对照的研究方法将87例年龄大于60岁的冠心病高胆固醇血症患者按入院次序随机分为瑞舒伐他汀组（44例）和辛伐他汀组（43例）.瑞舒伐他汀组给予瑞舒伐他汀10 mg,1次/d;辛伐他汀组给予辛伐他汀20 mg,1次/d,疗程8周,观察两药的疗效及安全性.结果 瑞舒伐他汀组经8周治疗,血浆LDL-C下降幅度（43.2%）明显大于辛伐他汀组（35.3%）,差异有统计学意义（P〈0.05）,瑞舒伐他汀组LDL-C达标率（85.1%）明显高于辛伐他汀组（59.8%）,差异有统计学意义（P〈0.05）;瑞舒伐他汀组HDL-C升高幅度（6.5%）也明显大于辛伐他汀组（1.6%）,2组比较差异具有统计学意义（P〈0.05）;瑞舒伐他汀组TC、TG降低幅度（分别为32.2%,17.O%）略优于辛伐他汀组（30.8%,15.2%）,2组比较差异无统计学意义（P〉0.05）.患者用药过程中无严重不良事件发生,主要不良反应为轻度腹胀、乏力,2组间不良反应发生率比较差异无统计学意义.结论 对老年冠心病高胆固醇血症人群,瑞舒伐他汀具有更强的降脂效果和良好的安全性.

Objective To evaluate the efficacy and safety of rosuvastatin in aged patients with coronary heart disease and hypercholesterolemia.Methods The selected patients were randomly divided into the rosuvastatin group（n=44,rosuvastatin 10 mg,qn）and simvastatin group（n=43,simvastatin 20 mg,qn）for 8 weeks.Results After treatment of 8 weeks,the decrease of plasma low-density lipoprotein cholesterol（LDL-C）in rosuvastatin group （43.2%） was significantly greater than that of simvastatin group（35.3%）（P〈0.05）.Compliance rate of LDL-C in rosuvastatin group（85.1% was higher than that in the simvastatin group （59.8%）.The rate of HDL-C increase in rosuvastatin group（6.5%） was significantly greater than that in simvastatin group （1.6%）（P〈0.05）.he rate of TC,TG decreasing in msuvastatin group （respectively 32.2%,17.0%） was slishfly better than that in the simvastatin group （30.8%VS 15.2%）,there was no significant difference between two groups（P〉0.05）.In this study the main adverse reactions were mild abdominal distension,fatigue.Conclusion For elderly people with coronary heart disease with hypercholestemlemia,rosuvastatin has a high lipid-lowering effect and good safety.